Greenwich-based ImmunoFree Inc. has appointed Dr. Ephraim Fuchs as chief medical officer.
In his new job, Fuchs will oversee all medical and scientific affairs of the company and be responsible for the development of the ImmunoFree tolerance protocol for transplant recipients who can benefit from the elimination of immunosuppressive medications.
Fuchs is a co-founder of ImmunoFree and a professor of oncology and immunology at the Johns Hopkins University School of Medicine. He is a world-renowned bone marrow transplant physician and researcher and is celebrated for conceiving and performing the first post-transplantation high-dose cyclophosphamide regimen for haploidentical bone marrow transplantation, which has become the standard of care in bone marrow transplant.
“I have known Ephraim for many years, and have seen his pioneering work in the field of cancer save thousands of lives,” said Dr. Robert Montgomery, co-founder of ImmunoFree and director of the New York University Transplant Institute. “I have also closely followed the science of immune-tolerance, and I cannot imagine a better person to fill the role of chief medical officer for ImmunoFree as we work to eliminate the need for immunosuppression medications and concurrently eliminate the side effects of those medications. Transplant tolerance has been a dream for over 30 years and we are on the verge of making it a reality.
